Meng Ying, Yang Peng, Ma Lili
Department of Stomatology, Liaocheng People's Hospital, Liaocheng City, Shandong Province, China.
Medicine (Baltimore). 2020 Jun 5;99(23):e20575. doi: 10.1097/MD.0000000000020575.
Recently, many studies have suggested that the aberrant expression of c-erbB-2 existed in oral cancer (OC) patients and had a correlation with poor clinical features across OC patients. Considering the inconsistent results among published articles, we performed the meta-analysis to assess the prognostic and clinical effect of c-erbB-2 expression on oral tumors.
Web of Science, Embase, and PubMed were retrieved to acquire relevant publications based on selection criteria, up to February 8, 2020. Pooled odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were applied to evaluate the associations between c-erbB-2 expression and overall survival (OS), disease specific survival, disease-free survival as well as clinicopathology of OC.
A total of 30 literatures with 1499 patients for survival of OC were enrolled in this meta-analysis. The results indicated that c-erbB-2 overexpression was significantly associated with poor OS (HR = 2.40, 95% CI = 1.53-2.55, P < .05), disease specific survival (HR = 2.60, 95% CI = 1.11-4.10, P < .05) and disease-free survival (HR = 2.22, 95% CI = 1.46-2.99, P < .05). Subgroup analysis based on race showed that the significant prognostic value of c-erbB-2 in OC was found both in Caucasians and Asians (OS of Caucasians, HR = 2.90, 95% CI = 1.50-4.31, P < .05; OS of Asians, HR = 1.90, 95% CI = 1.27-2.53, P < .05). Moreover, OC patients with enhanced c-erbB-2 expression were prone to male (OR = 1.97, 95% CI = 1.22-3.19, P < .05), advanced TNM stage (OR = 1.84, 95% CI = 1.17-2.88, P < .05), lymph node metastasis (OR = 2.23, 95% CI = 1.47-3.36, P < .05) and advanced grade (OR = 1.98, 95% CI = 1.30-3.01, P < .05), but not associated with distant metastasis (OR = 1.65, 95% CI = 0.98-3.04, P > .05).
c-erbB-2 may be a potential indicator in the prediction of prognosis and clinicopathological features in OC patients.
最近，许多研究表明，c-erbB-2在口腔癌（OC）患者中存在异常表达，并且与OC患者的不良临床特征相关。考虑到已发表文章的结果不一致，我们进行了荟萃分析，以评估c-erbB-2表达对口腔肿瘤的预后和临床影响。
检索Web of Science、Embase和PubMed，根据选择标准获取相关出版物，截至2020年2月8日。采用合并比值比（OR）和风险比（HR）以及95%置信区间（CI）来评估c-erbB-2表达与OC患者的总生存期（OS）、疾病特异性生存期、无病生存期以及临床病理特征之间的关联。
本荟萃分析共纳入30篇文献，涉及1499例OC患者的生存情况。结果表明，c-erbB-2过表达与较差的OS（HR = 2.40，95%CI = 1.53 - 2.55，P <.05）、疾病特异性生存期（HR = 2.60，95%CI = 1.11 - 4.10，P <.05）和无病生存期（HR = 2.22，95%CI = 1.
